Abstract
Epigenomic-wide DNA methylation profiling holds the potential to reflect both electronic cigarette exposure-associated risks and individual poor health outcomes. However, a systemic study in animals or humans is still lacking. Using the Infinium Mouse Methylation BeadChip, we examined the DNA methylation status of white blood cells in male ApoE-/- mice after 14 weeks of electronic cigarette exposure with the InExpose system (2 hr/day, 5 days/week, 50% PG and 50% VG) with low (6 mg/ml) and high (36 mg/ml) nicotine concentrations. Our results indicate that electronic cigarette aerosol inhalation induces significant alteration of 8,985 CpGs in a dose-dependent manner (FDR<0.05); 7,389 (82.2%) of the CpG sites are annotated with known genes. Among the top 6 significant CpG sites (P-value<1e-8), 4 CpG sites are located in the known genes, and most (3/5) of these genes have been related to cigarette smoking. The other two CpGs are close to/associated with the Phc2 gene that was recently linked to smoking in a transcriptome-wide associations study. Furthermore, the gene set enrichment analysis highlights the activation of MAPK and 4 cardiomyocyte/cardiomyopathy-related signaling pathways (including adrenergic signaling in cardiomyocytes and arrhythmogenic right ventricular cardiomyopathy) following repeated electronic cigarette use. The MAPK pathway activation correlates well with our finding of increased cytokine mRNA expression after electronic cigarette exposure in the same batch of mice. Interestingly, two pathways related to mitochondrial activities, namely mitochondrial gene expression and mitochondrial translation, are also activated after electronic cigarette exposure. Elucidating the relationship between these pathways and the increased circulating mitochondrial DNA observed here will provide further insight into the cell-damaging effects of prolonged inhalation of e-cigarette aerosols.
Keywords: Electronic cigarette, epigenomic-wide DNA methylation, dose-dependent, MAPK signaling pathway
Introduction
Introduced into the USA market in 2007 [1] as a healthy alternative to conventional cigarettes, e-cigarettes have experienced widespread acceptance among smokers, non-smokers, and especially the youth ever since [2]. The long-term health effects of e-cigarettes in humans are far from clear, and the causal inference study of e-cigarette user-health outcomes is time-consuming and costly. As an intermediate surrogate marker, DNA methylation does not change nucleotide sequences but partially determines chromatin structure and patterns of gene expression [3]. Results from traditional smoking and pilot studies of e-cigarette vaping suggest that the alteration of DNA methylation has the potential to reflect smoking/vaporing exposure and predict health effects, making it an ideal health biomarker of vaporing [4,5].
It has been well established that traditional cigarette smoking modulates DNA methylation in many CpG sites in an exposure concentration- and timing-dependent manner, suggesting that DNA methylation is induced not only by the exposure itself but also by the chemical concentration within the products [6-9]. The Epigenetic Smoking status Estimator, EpiSmokEr, is recently developed as a smoking status prediction tool by analyzing the DNA methylation pattern of peripheral blood cells with a machine learning algorithm (multinomial LASSO regression) [10]. In contrast to the extensive literature on cigarette-induced DNA methylation alteration, the study on e-cigarette-induced alteration of DNA methylation is in its early stage [11]. Using DNA from bronchial brushing samples of 32 subjects, Song et al. identified 451 differentially methylated CpGs at a false discovery rate (FDR) q<0.1; but in 97% of the CpGs methylation levels, e-cigarette users are between smokers and never-smokers [12]. Using leukocyte genomic DNA from 45 subjects, Caliri et al. showed that e-cigarette users and cigarette smokers have significant loss of methylation in LINE1 retroelements compared to controls [4]. These pilot studies clearly suggest that e-cigarette alters DNA methylation status; however, the small sample size and the limited number of DNA sequences analyzed make their results less conclusive or inclusive.
Extensive investigations in the last decade have suggested that DNA methylation signature is one of the determinant factors for human health, as methylation pattern partially shapes gene expression and sets up phenotypes, including potential initiation/progression of diseases and all-cause mortality [5]. In several common disorders, DNA methylation appears to explain a more significant portion of the measurable variance in complex traits than genetics [13,14]. In a study using 13 clinical traits in adipose tissue, methylation of the fatty acid synthase locus alone could account for 16% of BMI variation [15]. For comparison, 97 genetic variants identified in a large genome-wide association study explain merely 2.7% of the BMI variance [16]. Given the established critical role of genome-wide DNA methylation signature as a biomarker of cigarette smoking-induced health effects and exposure status predicator, we propose that genome-wide DNA methylation will also serve as a potential biomarker for e-cigarette vaping-induced systematic health effects and exposure status.
In the current study, ApoE-/- mice were divided into 3 groups based on different concentrations of nicotine in e-cigarettes (0, 6 mg/ml, and 36 mg/ml) and exposed for 14 weeks. Methylation of DNA from circulating white blood cells was profiled with Infinium Mouse Methylation BeadChip Kit, interrogated over 285,000 methylated CpGs in the promoters, gene bodies, and enhancer regions for genome-wide methylation at single-nucleotide resolution. Our results indicate e-cigarette induces extensive, dose-related alteration in the methylation pattern of DNA.
Material and methods
Animal use
5-week-old ApoE-/- mice were purchased from Jackson Laboratories (Bar Harbor, ME). All procedures were carried out following a protocol approved by Yale University Institutional Animal Care& Use Committee (IACUC).
E-cigarette exposure
In a series of experiments, mice were exposed to E-Cig vapor using the InExpose system specifically customized by Scientific Respiratory Equipment Inc. (Canada) for 2 hours/day, 5 days/week, for 14 weeks. The E-Cig formula (6 mg/ml or 36 mg/ml nicotine dissolved in 50% PG and 50% VG) and exposure setting were optimized according to the American E-Cig Liquid Manufacturing Standard and American Vaping Standard. Sixteen mice per group were subjected to whole-body exposure, while the control mice were exposed to HEPA filtered room air. At the experimental endpoint (12 hours after the last exposure), all mice were euthanized with CO2, followed by cervical dislocation. 500 µl of whole blood from each mouse was collected from vena cava, mixed with 50 µl of 1 unit/µl Heparin (H3393, Sigma), and subjected to flow cytometry for white blood cell sorting and to DNA extraction for epigenetic analysis.
Cotinine measurement
Successful intake of e-cigarettes after exposure was confirmed by mouse cotinine tests. The urine collection was done during the experimental endpoints and within 1 hour after the last E-Cig exposure. A mouse/Rat Cotinine ELISA kit (CO096D-100, Calbiotech Inc.) was used to measure the cotinine level, following the protocol supplied by the kit. All tests were performed at room temperature and read absorbance on the microplate reader at 450 nm within 15 minutes after adding the stopping buffer. The standard curve was used to quantify cotinine concentration in the tested samples.
Flow cytometry with whole blood samples
100 µl of anticoagulant-treated whole blood collected from animals at the experimental endpoint was subjected to red blood cell lysis, according to the manufacturer’s protocol. After red blood cell lysis, the remaining cells were stained with 4 fluorochrome-conjugated anti-mouse antibodies and analyzed on a FACSCanto LSRII flow cytometer (BD Biosciences). The antibody panel was designed based on various criteria, such as fluorochrome brightness, antigen density, co-expression, fluorochrome spillover of interested immune-cell subsets, and reagent availability in each panel for the available flow cytometer. Isotype controls were used to set the appropriate gate. Data were acquired with FACSDiva and analyzed with FlowJo 6.4.7v10.6. Approximately 20,000 cells were used to generate a scatter plot for each sample.
Blood cell DNA extraction, processing, and methylation profiling
Anticoagulant-treated mouse blood was centrifuged at 3500 rpm for 15 minutes to isolate the white blood cells and plasma. Both white blood cells and plasma were stored at -80°C for future tests. The Qiagen DNeasy Blood & Tissue kit (69506, Qiagen) was used for DNA extraction from the white blood cells. The extracted DNA was quantitated with a Qubit quantification assay (Thermo Fisher Scientific, Ecublens, Switzerland). Bisulfite-converted DNA was amplified and hybridized with Infinium Mouse Methylation BeadChip, including >285,000 markers (Illumina, CA, USA), and then scanned with Illumina iScan system (Illumina, CA, USA), following the manufacturer’s protocols.
Preprocessing of methylation data
DNA methylation data were preprocessed with the R package ‘Enmix’ [17]. Methylation data were first corrected for dye bias with the RELIC method [18] and then were quantile normalized. For quality control (QC), the samples with more than 5% of all CpG sites with a detection P-value larger than 0.01 and samples with mismatched sex between phenotype data and methylation data were removed. At the CpG level, CpG sites with a detection P-value larger than 0.01 in more than 5% of all samples (more than 1 sample in this study) were removed. Only CpG sites on autosomes were studied, and the CpG sites on sex chromosomes were removed in this study. Principal component analysis of all CpG sites that passed QC was used to find whether there were any outliers or clusters in the samples.
Identification of CpG sites with methylation changing according to e-cigarette exposure dose
A linear regression model listed below was used to discover CpG sites in which the methylation level changes with e-cigarette exposure dose. There are 3 levels of dosage, namely 0, 6, and 36 mg/ml.
M = β 0 + β 1 * Dose
M is the log2 ratio of methylation over unmethylation. We used the M value, which is more statistically valid than the Beta value, the proportion of methylation, for statistical analysis, Beta value, which has a more intuitive biological interpretation, for figure demonstration [19].
Besides dose-based analysis, we also used t-test after dichotomizing the data into two different pairs of groups: 0 mg/ml group vs. 6 mg/ml + 36 mg/ml group and 0 mg/ml + 6 mg/ml group vs. 36 mg/ml group.
Gene set enrichment analysis
To identify potential functions of the genes associated with significant CpG sites, we performed gene set enrichment analysis using the R package ‘clusterProfiler’ [20] on the gene sets in the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO). We first identified genes associated with any significant CpG sites as significant genes. Then we only focused on genes with significant CpG sites in their promoter region for the enrichment analysis.
Plasma cfDNA and mtDNA/nDNA ratio and oxidization of cell-free DNA
For measurement of in vivo plasma mtDNA/nDNA ratio, mice plasma was first subjected to cell-free DNA (cfDNA) extraction using Apostle minimax cfDNA extraction kit (ApostleBio, CA, US). Plasma cfDNAs were then used as templates for SYBR qPCR (Applied Biosystem, CA) with primers: murine 18S rDNA F: TAGAGGGACAAGTGGCGTTC; murine 18S rDNA R: CGCTGAGCCAGTCAGTGT; murine mtCO-1 F: GCCCCAGATATAGCATTCCC; murine mtCO-1 R: GTTCATCCTGTTCCTGCTCC. Amplification conditions were 95°C in 10 min; 95°C in 30 sec, 53°C in 30 sec for 40 cycles; followed by dissociation at 72°C in 30 sec, 95°C in 1 min, 55°C in 30 sec, and 95°C in 30 sec. The plasma mtDNA/nDNA ratio was calculated as the ratio of mtCO-1/18S rDNA. The relative fold-change of mtDNA was calculated using the 2-ΔΔCt method and compared to the control air group.
6.25 µl of a plasma sample from each mouse was used to do the DNA oxidization ELISA test using the DNA Damage Competitive ELISA Kit (EIADNAD, Invitrogen). 8-OHdG level in plasma can be used to indicate the DNA oxidization.
All data were collated using Microsoft Excel Software and analyzed using GraphPad Prism 5.0 (GraphPad, La Jolla, CA). All data are represented as the mean values, and error bars represent the mean’s standard error (SEM). Samples in experimental cohorts were compared using Dunnett’s multiple comparisons test. The difference was considered significant when P<0.05.
Results
E-cigarette exposure and blood cell component
The rodent whole body E-cigarette exposure system adopted in our study has been widely used and reported [21,22]. Successful and dose-dependent E-cigarette exposure was confirmed by measuring urine cotinine levels, which average at 0, 100, or 300,000 ng/ml for E-cigarette exposure with the nicotine dose at 0, 6, or 36 mg/ml, respectively (Figure S1). It is known that the DNA methylation in white blood cells could be influenced by the proportion of sub-compositions. A flow cytometry analysis of white blood cells showed that E-cigarette exposed mice had no significant change in the ratio of B lymphocytes, neutrophils, T lymphocytes, and monocytes when compared to air-exposed mice (Figure S2).
Preprocessing of methylation data
After removing CpGs with low quality and CpGs on chromosomes X and Y, there were 264,286 CpG sites left. Principal component analysis of the remaining CpG sites revealed differences among the three dose groups. The samples in each dose group were more likely to be clustered together. And we did not find any outliers from PCA (Figure 1). There were two peaks in the Beta value distribution (Figure 2), similar to the human methylation profile [23] and consistent with the other mouse methylation study [24]. After QC, all samples were then subject to the following analyses.
CpG sites with methylation changing related to e-cigarette exposure dose
One unique design in the current study is the nicotine dose escalation, which is not easily evaluated in human e-cigarette vapers, as most studies are based on self-reported e-cigarette use. However, few human studies on traditional cigarette smokers have examined the potential nicotine dose-escalated effects on DNA methylation of white blood cells. We calculated the P-value for each CpG site in the regression model. A Manhattan plot of the CpG sites was shown in Figure 3. We observed 8,985 CpG sites that were significantly associated with e-cigarette exposure dose (FDR<0.05, Table S1). Among them, 7,389 sites (82.2%) were annotated with known genes, and 2,492 sites (27.7%) were in the promoter regions of these genes (Transcription Start Site [TSS] 200, TSS1500). Figure 4 shows the correlation between nicotine doses and methylation levels of the top 6 significant CpG sites (P-value<1e-8). Two of them were inversely associated with e-cigarette exposure dosages, while the other four were positively associated with e-cigarette exposure dosages. 4 CpG sites were located in the known genes (cg44389073: Capns1; cg34735002: Znf598; cg46803463: Ccdc33 and Stra6; cg30601292: Tac4). Capns1 was found differentially expressed in a subpopulation of airway peri-goblet cells of smokers [25]. Znf598 was among the top 50 smoking-dysregulated genes in human airway basal cells [26]. Ccdc33 was also found to be influenced by smoking [27,28]. Although not mapped to any known gene, cg41445486 was very close to Phc2, a risk gene linked to smoking [29], and miRNA expression changes in the smokers’ spermatozoa [30]. Phc2 was also associated with smoking in a transcriptome-wide associations study (http://twas-hub.org/traits/UKBB_SMOKING_STATUS/) [31]. Another CpG site, cg41446118, which is significantly associated with e-cigarette exposure in a dose-dependent manner (FDR=0.005), was also located in the gene body of Phc2 (Table S1).
In the analyses of the data after dichotomization, we discovered 8,965 and 9,528 significant CpG sites for 0 mg/ml group vs. 6 mg/ml + 36 mg/ml group and 0 mg/ml + 6 mg/ml group vs. 36 mg/ml group, respectively (FDR<0.05, Tables S2, S3). The overlaps of significant CpG sites from the 3 analyses can be found in Figure S3. 75.2% of significant CpG sites found in dose analysis are overlapped with the results from at least one of the dichotomized analyses. It is a validation of the dose analysis.
Significant gene sets associated with e-cigarette exposure dose
The studies from our group and others indicate that e-cigarette exposure resulted in systematic inflammation, as illustrated by increased cytokine expression. The recurring inflammation is partly triggered by TLR9 activation from elevated cytoplasmic and/or circulating mitochondrial DNA [32]. Electronic cigarette exposure significantly increased right ventricle free wall thickness at systole and diastole in C57BL/6 wild-type mice [33]. Recent evidence also showed that e-cigarettes decreased left fractional ventricular shortening and ejection fraction in a mouse model [34].
The gene set enrichment analysis with E-cigarette exposure was conducted using the R package ‘clusterProfiler’. In the KEGG analysis, 33 gene pathways were enriched. The MAPK signaling pathways were at the top of the list and clearly related to the elevated cytokine expression after E-cigarette exposure. Four cardiomyocyte/cardiomyopathy-related pathways, including adrenergic signaling in cardiomyocytes, dilated cardiomyopathy, hypertrophic cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy, were also included in the top 10 gene pathway list (Figure 5, Table S4). The top 10 list from gene promoter analysis using GO highlighted two pathways related to mitochondrial activities: mitochondrial gene expression and mitochondrial translation (Figure 6, Table S5).
E-cigarette exposure results in increased mt/nDNA ratio and enhanced cfDNA oxidization
Circulating mitochondrial DNA is a pro-inflammatory damage-associated molecular pattern that triggers the formation of neutrophil extracellular traps in sickle cell disease [35]. It has been proposed as a biomarker for atrial fibrillation and coronary heart disease development in diabetic patients [36,37]. Our study showed that long-term e-cigarette exposure induced an increased mtDNA/nDNA ratio in a nicotine dose-dependent manner (Figure 7), indicating that mitochondrial function has been affected after the E-cigarette exposure. The elevated mtDNA could be responsible for activating toll-like receptor 9 and resulted in cytokine mRNA expression in cultured monocyte and elevated plasma cytokine protein levels after e-cigarette exposure observed in our previous study [32]. Both cigarette smoking and e-cigarette vaporing have enhanced oxidative stress in cells and circulation [38]. In the current study, we illustrated that long-term e-cigarette exposure enhances oxidized cfDNA levels in a nicotine dose-dependent pattern (Figure 8).
Discussion
Most E-cigarette vaporing studies measure the exposure via self-report or nicotine metabolites such as cotinine levels. Self-reporting method is the most direct measurement of external vaporing, but it fails to measure the absorbed vapor. Although cotinine could serve as an internal dose of vaporing, it is only a short-term marker and could not reflect the long-term exposure, which is critical for evaluating health effects accumulated through vaporing. DNA methylation is a well-established epigenetic biomarker, with unique profiles after exposure to air pollutants, heavy metals, and cigarette smoking [39,40]. Our study represents the first investigation to explore the whole-genomic DNA methylation alterations in white blood cells after long-term e-cigarette exposure. Our results indicate that e-cigarettes induced extensive alteration of DNA methylation in white blood cells in a nicotine dose-dependent pattern. Several CpG methylated sites unique to e-cigarettes may be used as biomarkers to assess long-term e-cigarette exposure. For the first time, our results reveal the alteration of genome-wide DNA methylation of circulating white blood cells after long-term e-cigarette exposure. These findings provide strong evidence to support the use of DNA methylation as a potential biomarker for the health effects of e-cigarette exposure.
One unique design of our study is the dose-escalation, which is not easily evaluated by human e-cigarette vapers. However, dose escalation results are not only compelling to confirm regulating effect of e-cigarettes on a CpG point but also have the potential to identify e-cigarette doses with less harmful health effects. Currently, no study in the current literature investigated dose-related DNA methylation effects of E-cigarette vaporing, and only a few studies discuss the dose-related methylation alterations in human smokers. In a study published in 2016, Zhang Y et al. demonstrated that methylation of 40 CpGs, mapped to 22 genes, was significantly associated with individual serum cotinine levels. The strongest association was found for AHHR cg05575921. A 10 ng/ml upregulation of cotinine resulted in a 3% lower methylation at AHHR cg05575921 [41]. This observation was confirmed by Prince C et al. in a study, which showed that methylations of cg05575921 and cg26703534 in smokers were both mapped to AHRR and strongly associated with blood cotinine levels [42]; dose-response in methylation at Cg05575921 was also related to the duration of smoking. In another study published in 2018, Park SL et al. showed increasing methylation beta-values of smokers in six CpG sites at higher levels of urinary nicotine metabolites. Four CpG sites were annotated in or near the FOXK2, PBX1, FNDC7, and FUBP3 genes; two other locations in non-annotated genetic regions [43].
The altered CpG site methylation status shown in our results overlapped with previous reports of DNA methylation after e-cigarette exposure. In a study including 117 smokers, 117 non-smokers, and 116 non-smoking vapers, epigenome-wide DNA methylation profiling from saliva revealed 7 CpG sites related to e-cigarette use at P<1×10-5. The CpG sites linked to e-cigarette use were largely distinct from those related to smoking. Consistent with this finding, our study showed that 3 out of those 7 genes, including acyl-CoA dehydrogenase 10 (ACAD10), semaphorin 5B, and immunoglobin superfamily member 21, also contained CpG sites with significantly altered methylation status [44]. Semaphorin 5B gene upregulation was also identified in another study using ApoE-/- mice after intermittent electronic cigarette exposure [34]. The altered CpG site methylation related to semaphorin 5B was also recognized in human smokers [45]. Previous studies also confirmed that 4 of the top 6 significant genes related to nicotine dosage in the e-cigarette, Capns1, Znf598, Ccdc33, and Phc2, were associated with cigarette smoking [25-30]. The biological activities of these CpG site-associated genes are interesting. ACAD10 has been linked to type 2 diabetes [46] and hypertension [47]: ACAD10-deficient mice exhibited abnormal glucose tolerance and elevated insulin level, accumulated excess abdominal adipose tissue, and developed an early inflammatory liver process [48]. Phc2 was identified as a critical modulator of hematopoietic stem and progenitor cell (HSPC) trafficking. Genetic knockout of Phc2 in mice results in a severe defect in HSPC mobilization by depressing Vcam1 expression in bone marrow stromal cells, finally ending up with a systemic immunodeficiency [49].
Smoking is well known to be associated with systemic and local inflammation in the lungs, and higher tobacco consumption is associated with higher systemic inflammation both genetically and observationally [50]. Pro-inflammatory pathways are upregulated, and anti-inflammatory ones are downregulated for smoking exposure. Inflammatory cytokines such as TNFα, IL6, and RANTES are induced by smoking [51,52]. The previous studies reported by our group and the others have shown that e-cigarette use/exposure results in systematic and local inflammation [32,53]. The above observation correlates very well with the gene set enrichment KEGG pathway analysis, which showed MAPK signaling pathway is the most significant one in our study. It is conceivable that E-cigarette exposure induces a systematic pro-inflammatory environment by releasing growth factors and cytokines. These inflammatory agents activate the MAPK signaling pathways, further exacerbating the inflammatory process.
Mitochondria are organelles involved in many physiological and pathological functions. Recent evidence showed that it could also play a role as a regulator of the innate immune response [54]. mtDNA is ideal for inducing an innate immune response via its escape from the mitochondria to other organelles, the cytosol, and the extracellular space. Additionally, our previous study has shown cytoplasmic mtDNA activates toll-like receptor 9 in monocytes/macrophages and triggers the inflammatory process [32]. The released mtDNA in the cytosol could also be recognized by other DNA sensors, including cGAS, a cGAMP, whose activation leads to an enhanced expression of type I interferons and active pro-inflammatory cytokines IL-1β. Interaction of mtDNA with the cGAS-STING signaling axis has been described in multiple pathological conditions, which share the final common pathway of leakage of mtDNA from mitochondria to the cytosol [55]. Our data showed that cfDNA in the plasma contained more mtDNA after the E-cigarette exposure, illustrated by an increased mtDNA/ncDNA ratio, indicating that the damaged mtDNA was released from the cytoplasm to the plasma. In the DNA methylation profiling data, two mitochondrial function-related pathways have been affected based on the GO pathway analysis in the promotor region, including mitochondrial gene expression and mitochondrial translation. The dysfunction of mitochondria under the multiple stresses may cause the release of mtDNA, but the mechanisms triggering the release are still not fully understood. It is known that loss of mitophage [56] (selective autophagy process in which damaged mitochondria are targeted for lysosomal degradation), cytosolic ROS induced mitochondrial permeability transition [57], and opening of mitochondrial permeability transition pore [58] are several mechanisms for mtDNA release into the cytosol. Whether mitochondrial transcription and translocation are biomarkers for any of the mechanisms above is unknown. Elucidating the relationship between these pathways and the increased circulating mitochondrial DNA observed here will provide further insight into the cell-damaging effects of prolonged inhalation of e-cigarette aerosols.
In conclusion, our study reveals that e-cigarette exposure results in extensive DNA methylation alteration in male ApoE-/- mice in a dose-dependent manner of nicotine. Our epigenomic-wide CpG site methylation pattern overlaps with previously published methylation sites in vapers/smokers. The methylation pattern correlates well with enhanced systematic inflammation reported in animal models and human vapers.
Acknowledgements
This research was supported in part by a Career Enhancement Program Grant from the Yale Head and Neck SPORE, P50 DE030707.
Disclosure of conflict of interest
None.
Table S1
Table S2
Table S3
Figures S1-S3 and Tables S4, S5
References
- 1.Krishnan-Sarin S, Jackson A, Morean M, Kong G, Bold KW, Camenga DR, Cavallo DA, Simon P, Wu R. E-cigarette devices used by high-school youth. Drug Alcohol Depend. 2019;194:395–400. doi: 10.1016/j.drugalcdep.2018.10.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Fadus MC, Smith TT, Squeglia LM. The rise of e-cigarettes, pod mod devices, and JUUL among youth: factors influencing use, health implications, and downstream effects. Drug Alcohol Depend. 2019;201:85–93. doi: 10.1016/j.drugalcdep.2019.04.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Parry A, Rulands S, Reik W. Active turnover of DNA methylation during cell fate decisions. Nat Rev Genet. 2021;22:59–66. doi: 10.1038/s41576-020-00287-8. [DOI] [PubMed] [Google Scholar]
- 4.Caliri AW, Caceres A, Tommasi S, Besaratinia A. Hypomethylation of LINE-1 repeat elements and global loss of DNA hydroxymethylation in vapers and smokers. Epigenetics. 2020;15:816–829. doi: 10.1080/15592294.2020.1724401. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Suhre K, Zaghlool S. Connecting the epigenome, metabolome and proteome for a deeper understanding of disease. J Intern Med. 2021;290:527–548. doi: 10.1111/joim.13306. [DOI] [PubMed] [Google Scholar]
- 6.Bollepalli S, Korhonen T, Kaprio J, Anders S, Ollikainen M. EpiSmokEr: a robust classifier to determine smoking status from DNA methylation data. Epigenomics. 2019;11:1469–1486. doi: 10.2217/epi-2019-0206. [DOI] [PubMed] [Google Scholar]
- 7.Joehanes R, Just AC, Marioni RE, Pilling LC, Reynolds LM, Mandaviya PR, Guan W, Xu T, Elks CE, Aslibekyan S, Moreno-Macias H, Smith JA, Brody JA, Dhingra R, Yousefi P, Pankow JS, Kunze S, Shah SH, McRae AF, Lohman K, Sha J, Absher DM, Ferrucci L, Zhao W, Demerath EW, Bressler J, Grove ML, Huan T, Liu C, Mendelson MM, Yao C, Kiel DP, Peters A, Wang-Sattler R, Visscher PM, Wray NR, Starr JM, Ding J, Rodriguez CJ, Wareham NJ, Irvin MR, Zhi D, Barrdahl M, Vineis P, Ambatipudi S, Uitterlinden AG, Hofman A, Schwartz J, Colicino E, Hou L, Vokonas PS, Hernandez DG, Singleton AB, Bandinelli S, Turner ST, Ware EB, Smith AK, Klengel T, Binder EB, Psaty BM, Taylor KD, Gharib SA, Swenson BR, Liang L, DeMeo DL, O’Connor GT, Herceg Z, Ressler KJ, Conneely KN, Sotoodehnia N, Kardia SL, Melzer D, Baccarelli AA, van Meurs JB, Romieu I, Arnett DK, Ong KK, Liu Y, Waldenberger M, Deary IJ, Fornage M, Levy D, London SJ. Epigenetic signatures of cigarette smoking. Circ Cardiovasc Genet. 2016;9:436–447. doi: 10.1161/CIRCGENETICS.116.001506. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.McCartney DL, Stevenson AJ, Hillary RF, Walker RM, Bermingham ML, Morris SW, Clarke TK, Campbell A, Murray AD, Whalley HC, Porteous DJ, Visscher PM, McIntosh AM, Evans KL, Deary IJ, Marioni RE. Epigenetic signatures of starting and stopping smoking. EBioMedicine. 2018;37:214–220. doi: 10.1016/j.ebiom.2018.10.051. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Zeilinger S, Kuhnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, Weidinger S, Lattka E, Adamski J, Peters A, Strauch K, Waldenberger M, Illig T. Tobacco smoking leads to extensive genome-wide changes in DNA methylation. PLoS One. 2013;8:e63812. doi: 10.1371/journal.pone.0063812. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Ligthart S, Marzi C, Aslibekyan S, Mendelson MM, Conneely KN, Tanaka T, Colicino E, Waite LL, Joehanes R, Guan W, Brody JA, Elks C, Marioni R, Jhun MA, Agha G, Bressler J, Ward-Caviness CK, Chen BH, Huan T, Bakulski K, Salfati EL WHI-EMPC Investigators; Fiorito G CHARGE epigenetics of Coronary Heart Disease. Wahl S, Schramm K, Sha J, Hernandez DG, Just AC, Smith JA, Sotoodehnia N, Pilling LC, Pankow JS, Tsao PS, Liu C, Zhao W, Guarrera S, Michopoulos VJ, Smith AK, Peters MJ, Melzer D, Vokonas P, Fornage M, Prokisch H, Bis JC, Chu AY, Herder C, Grallert H, Yao C, Shah S, McRae AF, Lin H, Horvath S, Fallin D, Hofman A, Wareham NJ, Wiggins KL, Feinberg AP, Starr JM, Visscher PM, Murabito JM, Kardia SL, Absher DM, Binder EB, Singleton AB, Bandinelli S, Peters A, Waldenberger M, Matullo G, Schwartz JD, Demerath EW, Uitterlinden AG, van Meurs JB, Franco OH, Chen YI, Levy D, Turner ST, Deary IJ, Ressler KJ, Dupuis J, Ferrucci L, Ong KK, Assimes TL, Boerwinkle E, Koenig W, Arnett DK, Baccarelli AA, Benjamin EJ, Dehghan A. DNA methylation signatures of chronic low-grade inflammation are associated with complex diseases. Genome Biol. 2016;17:255. doi: 10.1186/s13059-016-1119-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Andersen A, Reimer R, Dawes K, Becker A, Hutchens N, Miller S, Dogan M, Hundley B, J AM, J DL, Philibert R. DNA methylation differentiates smoking from vaping and non-combustible tobacco use. Epigenetics. 2022;17:178–190. doi: 10.1080/15592294.2021.1890875. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Song MA, Freudenheim JL, Brasky TM, Mathe EA, McElroy JP, Nickerson QA, Reisinger SA, Smiraglia DJ, Weng DY, Ying KL, Wewers MD, Shields PG. Biomarkers of exposure and effect in the lungs of smokers, non-smokers, and electronic cigarette users. Cancer Epidemiol Biomarkers Prev. 2020;29:443–451. doi: 10.1158/1055-9965.EPI-19-1245. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Liang L, Willis-Owen SAG, Laprise C, Wong KCC, Davies GA, Hudson TJ, Binia A, Hopkin JM, Yang IV, Grundberg E, Busche S, Hudson M, Ronnblom L, Pastinen TM, Schwartz DA, Lathrop GM, Moffatt MF, Cookson WOCM. An epigenome-wide association study of total serum immunoglobulin E concentration. Nature. 2015;520:670–674. doi: 10.1038/nature14125. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Juvinao-Quintero DL, Marioni RE, Ochoa-Rosales C, Russ TC, Deary IJ, van Meurs JBJ, Voortman T, Hivert MF, Sharp GC, Relton CL, Elliott HR. DNA methylation of blood cells is associated with prevalent type 2 diabetes in a meta-analysis of four European cohorts. Clin Epigenetics. 2021;13:40. doi: 10.1186/s13148-021-01027-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Orozco LD, Farrell C, Hale C, Rubbi L, Rinaldi A, Civelek M, Pan C, Lam L, Montoya D, Edillor C, Seldin M, Boehnke M, Mohlke KL, Jacobsen S, Kuusisto J, Laakso M, Lusis AJ, Pellegrini M. Epigenome-wide association in adipose tissue from the METSIM cohort. Hum Mol Genet. 2018;27:2586. doi: 10.1093/hmg/ddy205. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, Croteau-Chonka DC, Esko T, Fall T, Ferreira T, Gustafsson S, Kutalik Z, Luan J, Magi R, Randall JC, Winkler TW, Wood AR, Workalemahu T, Faul JD, Smith JA, Zhao JH, Zhao W, Chen J, Fehrmann R, Hedman AK, Karjalainen J, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M, Bolton JL, Bragg-Gresham JL, Buyske S, Demirkan A, Deng G, Ehret GB, Feenstra B, Feitosa MF, Fischer K, Goel A, Gong J, Jackson AU, Kanoni S, Kleber ME, Kristiansson K, Lim U, Lotay V, Mangino M, Leach IM, Medina-Gomez C, Medland SE, Nalls MA, Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Shungin D, Stancakova A, Strawbridge RJ, Sung YJ, Tanaka T, Teumer A, Trompet S, van der Laan SW, van Setten J, Van Vliet-Ostaptchouk JV, Wang Z, Yengo L, Zhang W, Isaacs A, Albrecht E, Arnlov J, Arscott GM, Attwood AP, Bandinelli S, Barrett A, Bas IN, Bellis C, Bennett AJ, Berne C, Blagieva R, Bluher M, Bohringer S, Bonnycastle LL, Bottcher Y, Boyd HA, Bruinenberg M, Caspersen IH, Chen YI, Clarke R, Daw EW, de Craen AJM, Delgado G, Dimitriou M, Doney ASF, Eklund N, Estrada K, Eury E, Folkersen L, Fraser RM, Garcia ME, Geller F, Giedraitis V, Gigante B, Go AS, Golay A, Goodall AH, Gordon SD, Gorski M, Grabe HJ, Grallert H, Grammer TB, Grassler J, Gronberg H, Groves CJ, Gusto G, Haessler J, Hall P, Haller T, Hallmans G, Hartman CA, Hassinen M, Hayward C, Heard-Costa NL, Helmer Q, Hengstenberg C, Holmen O, Hottenga JJ, James AL, Jeff JM, Johansson A, Jolley J, Juliusdottir T, Kinnunen L, Koenig W, Koskenvuo M, Kratzer W, Laitinen J, Lamina C, Leander K, Lee NR, Lichtner P, Lind L, Lindstrom J, Lo KS, Lobbens S, Lorbeer R, Lu Y, Mach F, Magnusson PKE, Mahajan A, McArdle WL, McLachlan S, Menni C, Merger S, Mihailov E, Milani L, Moayyeri A, Monda KL, Morken MA, Mulas A, Muller G, Muller-Nurasyid M, Musk AW, Nagaraja R, Nothen MM, Nolte IM, Pilz S, Rayner NW, Renstrom F, Rettig R, Ried JS, Ripke S, Robertson NR, Rose LM, Sanna S, Scharnagl H, Scholtens S, Schumacher FR, Scott WR, Seufferlein T, Shi J, Smith AV, Smolonska J, Stanton AV, Steinthorsdottir V, Stirrups K, Stringham HM, Sundstrom J, Swertz MA, Swift AJ, Syvanen AC, Tan ST, Tayo BO, Thorand B, Thorleifsson G, Tyrer JP, Uh HW, Vandenput L, Verhulst FC, Vermeulen SH, Verweij N, Vonk JM, Waite LL, Warren HR, Waterworth D, Weedon MN, Wilkens LR, Willenborg C, Wilsgaard T, Wojczynski MK, Wong A, Wright AF, Zhang Q, LifeLines Cohort S, Brennan EP, Choi M, Dastani Z, Drong AW, Eriksson P, Franco-Cereceda A, Gadin JR, Gharavi AG, Goddard ME, Handsaker RE, Huang J, Karpe F, Kathiresan S, Keildson S, Kiryluk K, Kubo M, Lee JY, Liang L, Lifton RP, Ma B, McCarroll SA, McKnight AJ, Min JL, Moffatt MF, Montgomery GW, Murabito JM, Nicholson G, Nyholt DR, Okada Y, Perry JRB, Dorajoo R, Reinmaa E, Salem RM, Sandholm N, Scott RA, Stolk L, Takahashi A, Tanaka T, van ’t Hooft FM, Vinkhuyzen AAE, Westra HJ, Zheng W, Zondervan KT ADIPOGen Consortium; AGEN-BMI Working Group; CARDIOGRAMplusC4D Consortium; CKDGen Consortium; GLGC; ICBP; MAGIC Investigators; MuTHER Consortium; MIGen Consortium; PAGE Consortium; ReproGen Consortium; GENIE Consortium; International Endogene Consortium. Heath AC, Arveiler D, Bakker SJL, Beilby J, Bergman RN, Blangero J, Bovet P, Campbell H, Caulfield MJ, Cesana G, Chakravarti A, Chasman DI, Chines PS, Collins FS, Crawford DC, Cupples LA, Cusi D, Danesh J, de Faire U, den Ruijter HM, Dominiczak AF, Erbel R, Erdmann J, Eriksson JG, Farrall M, Felix SB, Ferrannini E, Ferrieres J, Ford I, Forouhi NG, Forrester T, Franco OH, Gansevoort RT, Gejman PV, Gieger C, Gottesman O, Gudnason V, Gyllensten U, Hall AS, Harris TB, Hattersley AT, Hicks AA, Hindorff LA, Hingorani AD, Hofman A, Homuth G, Hovingh GK, Humphries SE, Hunt SC, Hypponen E, Illig T, Jacobs KB, Jarvelin MR, Jockel KH, Johansen B, Jousilahti P, Jukema JW, Jula AM, Kaprio J, Kastelein JJP, Keinanen-Kiukaanniemi SM, Kiemeney LA, Knekt P, Kooner JS, Kooperberg C, Kovacs P, Kraja AT, Kumari M, Kuusisto J, Lakka TA, Langenberg C, Marchand LL, Lehtimaki T, Lyssenko V, Mannisto S, Marette A, Matise TC, McKenzie CA, McKnight B, Moll FL, Morris AD, Morris AP, Murray JC, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Madden PAF, Pasterkamp G, Peden JF, Peters A, Postma DS, Pramstaller PP, Price JF, Qi L, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker PM, Rioux JD, Ritchie MD, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schunkert H, Schwarz PEH, Sever P, Shuldiner AR, Sinisalo J, Stolk RP, Strauch K, Tonjes A, Tregouet DA, Tremblay A, Tremoli E, Virtamo J, Vohl MC, Volker U, Waeber G, Willemsen G, Witteman JC, Zillikens MC, Adair LS, Amouyel P, Asselbergs FW, Assimes TL, Bochud M, Boehm BO, Boerwinkle E, Bornstein SR, Bottinger EP, Bouchard C, Cauchi S, Chambers JC, Chanock SJ, Cooper RS, de Bakker PIW, Dedoussis G, Ferrucci L, Franks PW, Froguel P, Groop LC, Haiman CA, Hamsten A, Hui J, Hunter DJ, Hveem K, Kaplan RC, Kivimaki M, Kuh D, Laakso M, Liu Y, Martin NG, Marz W, Melbye M, Metspalu A, Moebus S, Munroe PB, Njolstad I, Oostra BA, Palmer CNA, Pedersen NL, Perola M, Perusse L, Peters U, Power C, Quertermous T, Rauramaa R, Rivadeneira F, Saaristo TE, Saleheen D, Sattar N, Schadt EE, Schlessinger D, Slagboom PE, Snieder H, Spector TD, Thorsteinsdottir U, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Walker M, Wallaschofski H, Wareham NJ, Watkins H, Weir DR, Wichmann HE, Wilson JF, Zanen P, Borecki IB, Deloukas P, Fox CS, Heid IM, O’Connell JR, Strachan DP, Stefansson K, van Duijn CM, Abecasis GR, Franke L, Frayling TM, McCarthy MI, Visscher PM, Scherag A, Willer CJ, Boehnke M, Mohlke KL, Lindgren CM, Beckmann JS, Barroso I, North KE, Ingelsson E, Hirschhorn JN, Loos RJF, Speliotes EK. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518:197–206. doi: 10.1038/nature14177. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Xu ZL, Niu L, Li LP, Taylor JA. ENmix: a novel background correction method for Illumina HumanMethylation450 BeadChip. Nucleic Acids Res. 2016;44:e20. doi: 10.1093/nar/gkv907. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Xu ZL, Langie SA, De Boever P, Taylor JA, Niu L. RELIC: a novel dye-bias correction method for Illumina Methylation BeadChip. BMC Genomics. 2017;18:4. doi: 10.1186/s12864-016-3426-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou LF, Lin SM. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics. 2010;11:587. doi: 10.1186/1471-2105-11-587. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Wu TZ, Hu EQ, Xu SB, Chen MJ, Guo PF, Dai ZH, Feng TZ, Zhou L, Tang WL, Zhan L, Fu XC, Liu SS, Bo XC, Yu GC. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb) 2021;2:100141. doi: 10.1016/j.xinn.2021.100141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Richmond BW, Brucker RM, Han W, Du RH, Zhang Y, Cheng DS, Gleaves L, Abdolrasulnia R, Polosukhina D, Clark PE, Bordenstein SR, Blackwell TS, Polosukhin VV. Airway bacteria drive a progressive COPD-like phenotype in mice with polymeric immunoglobulin receptor deficiency. Nat Commun. 2016;7:11240. doi: 10.1038/ncomms11240. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Noel A, Verret CM, Hasan F, Lomnicki S, Morse J, Robichaud A, Penn AL. Generation of electronic cigarette aerosol by a third-generation machine-vaping device: application to toxicological studies. J Vis Exp. 2018:58095. doi: 10.3791/58095. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Pidsley R, Zotenko E, Peters TJ, Lawrence MG, Risbridger GP, Molloy P, Van Djik S, Muhlhausler B, Stirzaker C, Clark SJ. Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. Genome Biol. 2016;17:208. doi: 10.1186/s13059-016-1066-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Garcia-Prieto CA, Alvarez-Errico D, Musulen E, Bueno-Costa A, N Vazquez B, Vaquero A, Esteller M. Validation of a DNA methylation microarray for 285,000 CpG sites in the mouse genome. Epigenetics. 2022:1–9. doi: 10.1080/15592294.2022.2053816. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Duclos GE, Teixeira VH, Autissier P, Gesthalter YB, Reinders-Luinge MA, Terrano R, Dumas YM, Liu G, Mazzilli SA, Brandsma CA, van den Berge M, Janes SM, Timens W, Lenburg ME, Spira A, Campbell JD, Beane J. Characterizing smoking-induced transcriptional heterogeneity in the human bronchial epithelium at single-cell resolution. Sci Adv. 2019;5:eaaw3413. doi: 10.1126/sciadv.aaw3413. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Ryan DM, Vincent TL, Salit J, Walters MS, Agosto-Perez F, Shaykhiev R, Strulovici-Barel Y, Downey RJ, Buro-Auriemma LJ, Staudt MR, Hackett NR, Mezey JG, Crystal RG. Smoking dysregulates the human airway basal cell transcriptome at COPD risk locus 19q13.2. PLoS One. 2014;9:e88051. doi: 10.1371/journal.pone.0088051. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Beane J, Sebastiani P, Liu G, Brody JS, Lenburg ME, Spira A. Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression. Genome Biol. 2007;8:R201. doi: 10.1186/gb-2007-8-9-r201. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Fowler PA, Childs AJ, Courant F, MacKenzie A, Rhind SM, Antignac JP, Le Bizec B, Filis P, Evans F, Flannigan S, Maheshwari A, Bhattacharya S, Monteiro A, Anderson RA, O’Shaughnessy PJ. In utero exposure to cigarette smoke dysregulates human fetal ovarian developmental signalling. Hum Reprod. 2014;29:1471–1489. doi: 10.1093/humrep/deu117. [DOI] [PubMed] [Google Scholar]
- 29.Song WC, Lin GN, Yu SY, Zhao M. Genome-wide identification of the shared genetic basis of cannabis and cigarette smoking and schizophrenia implicates NCAM1 and neuronal abnormality. Psychiatry Res. 2022;310:114453. doi: 10.1016/j.psychres.2022.114453. [DOI] [PubMed] [Google Scholar]
- 30.Marczylo EL, Amoako AA, Konje JC, Gant TW, Marczylo TH. Smoking induces differential miRNA expression in human spermatozoa: a potential transgenerational epigenetic concern? Epigenetics. 2012;7:432–439. doi: 10.4161/epi.19794. [DOI] [PubMed] [Google Scholar]
- 31.Mancuso N, Shi H, Goddard P, Kichaev G, Gusev A, Pasaniuc B. Integrating gene expression with summary association statistics to identify genes associated with 30 complex traits. Am J Hum Genet. 2017;100:473–487. doi: 10.1016/j.ajhg.2017.01.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Li JL, Huynh L, Cornwell WD, Tang MS, Simborio H, Huang J, Kosmider B, Rogers TJ, Zhao HQ, Steinberg MB, Thu Thi Le L, Zhang LJ, Pham K, Liu C, Wang H. Electronic cigarettes induce mitochondrial DNA damage and trigger TLR9 (Toll-Like Receptor 9)-mediated atherosclerosis. Arterioscler Thromb Vasc Biol. 2021;41:839–853. doi: 10.1161/ATVBAHA.120.315556. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Getiye Y, Peterson MR, Phillips BD, Carrillo D, Bisha B, He GL. E-cigarette exposure with or without heating the e-liquid induces differential remodeling in the lungs and right heart of mice. J Mol Cell Cardiol. 2022;168:83–95. doi: 10.1016/j.yjmcc.2022.04.014. [DOI] [PubMed] [Google Scholar]
- 34.Espinoza-Derout J, Hasan KM, Shao XM, Jordan MC, Sims C, Lee DL, Sinha S, Simmons Z, Mtume N, Liu Y, Roos KP, Sinha-Hikim AP, Friedman TC. Chronic intermittent electronic cigarette exposure induces cardiac dysfunction and atherosclerosis in apolipoprotein-E knockout mice. Am J Physiol Heart Circ Physiol. 2019;317:H445–H459. doi: 10.1152/ajpheart.00738.2018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Tumburu L, Ghosh-Choudhary S, Seifuddin FT, Barbu EA, Yang S, Ahmad MM, Wilkins LHW, Tunc I, Sivakumar I, Nichols JS, Dagur PK, Yang S, Almeida LEF, Quezado ZMN, Combs CA, Lindberg E, Bleck CKE, Zhu J, Shet AS, Chung JH, Pirooznia M, Thein SL. Circulating mitochondrial DNA is a pro-inflammatory DAMP in sickle cell disease. Blood. 2021;137:3116–3126. doi: 10.1182/blood.2020009063. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Wiersma M, van Marion DMS, Bouman EJ, Li J, Zhang D, Ramos KS, Lanters EAH, de Groot NMS, Brundel BJJM. Cell-free circulating mitochondrial DNA: a potential blood-based marker for atrial fibrillation. Cells. 2020;9:1159. doi: 10.3390/cells9051159. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Liu J, Cai XM, Xie L, Tang Y, Cheng JH, Wang J, Wang LJ, Gong JB. Circulating cell free mitochondrial DNA is a biomarker in the development of coronary heart disease in the patients with Type 2 diabetes. Clin Lab. 2015;61:661–667. doi: 10.7754/clin.lab.2014.141132. [DOI] [PubMed] [Google Scholar]
- 38.Muthumalage T, Lamb T, Friedman MR, Rahman I. E-cigarette flavored pods induce inflammation, epithelial barrier dysfunction, and DNA damage in lung epithelial cells and monocytes. Sci Rep. 2019;9:19035. doi: 10.1038/s41598-019-51643-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Martin EM, Fry RC. Environmental influences on the epigenome: exposure- associated DNA methylation in human populations. Annu Rev Public Health. 2018;39:309–333. doi: 10.1146/annurev-publhealth-040617-014629. [DOI] [PubMed] [Google Scholar]
- 40.Long PP, Wang QH, Zhang YZ, Zhu XY, Yu K, Jiang HJ, Liu XZ, Zhou M, Yuan Y, Liu K, Jiang J, Zhang XM, He MA, Guo H, Chen WH, Yuan J, Cheng LX, Liang LM, Wu TC. Profile of copper-associated DNA methylation and its association with incident acute coronary syndrome. Clin Epigenetics. 2021;13:19. doi: 10.1186/s13148-021-01004-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Zhang Y, Florath I, Saum KU, Brenner H. Self-reported smoking, serum cotinine, and blood DNA methylation. Environ Res. 2016;146:395–403. doi: 10.1016/j.envres.2016.01.026. [DOI] [PubMed] [Google Scholar]
- 42.Prince C, Hammerton G, Taylor AE, Anderson EL, Timpson NJ, Davey Smith G, Munafo MR, Relton CL, Richmond RC. Investigating the impact of cigarette smoking behaviours on DNA methylation patterns in adolescence. Hum Mol Genet. 2019;28:155–165. doi: 10.1093/hmg/ddy316. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Park SL, Patel YM, Loo LWM, Mullen DJ, Offringa IA, Maunakea A, Stram DO, Siegmund K, Murphy SE, Tiirikainen M, Le Marchand L. Association of internal smoking dose with blood DNA methylation in three racial/ethnic populations. Clin Epigenetics. 2018;10:110. doi: 10.1186/s13148-018-0543-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Richmond RC, Sillero-Rejon C, Khouja JN, Prince C, Board A, Sharp G, Suderman M, Relton CL, Munafo M, Gage SH. Investigating the DNA methylation profile of e-cigarette use. Clin Epigenetics. 2021;13:183. doi: 10.1186/s13148-021-01174-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Gupta R, van Dongen J, Fu Y, Abdellaoui A, Tyndale RF, Velagapudi V, Boomsma DI, Korhonen T, Kaprio J, Loukola A, Ollikainen M. Epigenome-wide association study of serum cotinine in current smokers reveals novel genetically driven loci. Clin Epigenetics. 2019;11:1. doi: 10.1186/s13148-018-0606-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Bian L, Hanson RL, Muller YL, Ma L MAGIC Investigators. Kobes S, Knowler WC, Bogardus C, Baier LJ. Variants in ACAD10 are associated with type 2 diabetes, insulin resistance and lipid oxidation in Pima Indians. Diabetologia. 2010;53:1349–1353. doi: 10.1007/s00125-010-1695-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Yamada Y, Sakuma J, Takeuchi I, Yasukochi Y, Kato K, Oguri M, Fujimaki T, Horibe H, Muramatsu M, Sawabe M, Fujiwara Y, Taniguchi Y, Obuchi S, Kawai H, Shinkai S, Mori S, Arai T, Tanaka M. Identification of polymorphisms in 12q24.1, ACAD10, and BRAP as novel genetic determinants of blood pressure in Japanese by exome-wide association studies. Oncotarget. 2017;8:43068–43079. doi: 10.18632/oncotarget.17474. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Bloom K, Mohsen AW, Karunanidhi A, El Demellawy D, Reyes-Mugica M, Wang Y, Ghaloul-Gonzalez L, Otsubo C, Tobita K, Muzumdar R, Gong Z, Tas E, Basu S, Chen J, Bennett M, Hoppel C, Vockley J. Investigating the link of ACAD10 deficiency to type 2 diabetes mellitus. J Inherit Metab Dis. 2018;41:49–57. doi: 10.1007/s10545-017-0013-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Bae J, Choi SP, Isono K, Lee JY, Park SW, Choi CY, Han J, Kim SH, Lee HH, Park K, Jin HY, Lee SJ, Park CG, Koseki H, Lee YS, Chun T. Phc2 controls hematopoietic stem and progenitor cell mobilization from bone marrow by repressing Vcam1 expression. Nat Commun. 2019;10:3496. doi: 10.1038/s41467-019-11386-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Colak Y, Afzal S, Lange P, Nordestgaard BG. Smoking, systemic inflammation, and airflow limitation: a mendelian randomization analysis of 98 085 individuals from the general population. Nicotine Tob Res. 2019;21:1036–1044. doi: 10.1093/ntr/nty077. [DOI] [PubMed] [Google Scholar]
- 51.Gomes M, Teixeira AL, Coelho A, Araujo A, Medeiros R. The role of inflammation in lung cancer. Adv Exp Med Biol. 2014;816:1–23. doi: 10.1007/978-3-0348-0837-8_1. [DOI] [PubMed] [Google Scholar]
- 52.Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867. doi: 10.1038/nature01322. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Kotoulas SC, Pataka A, Domvri K, Spyratos D, Katsaounou P, Porpodis K, Fouka E, Markopoulou A, Passa-Fekete K, Grigoriou I, Kontakiotis T, Argyropoulou P, Papakosta D. Acute effects of e-cigarette vaping on pulmonary function and airway inflammation in healthy individuals and in patients with asthma. Respirology. 2020;25:1037–1045. doi: 10.1111/resp.13806. [DOI] [PubMed] [Google Scholar]
- 54.Herst PM, Rowe MR, Carson GM, Berridge MV. Functional mitochondria in health and disease. Front Endocrinol (Lausanne) 2017;8:296. doi: 10.3389/fendo.2017.00296. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.De Gaetano A, Solodka K, Zanini G, Selleri V, Mattioli AV, Nasi M, Pinti M. Molecular mechanisms of mtDNA-mediated inflammation. Cells. 2021;10:2898. doi: 10.3390/cells10112898. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Harris J, Deen N, Zamani S, Hasnat MA. Mitophagy and the release of inflammatory cytokines. Mitochondrion. 2018;41:2–8. doi: 10.1016/j.mito.2017.10.009. [DOI] [PubMed] [Google Scholar]
- 57.Bernardi P. The mitochondrial permeability transition pore: a mystery solved? Front Physiol. 2013;4:95. doi: 10.3389/fphys.2013.00095. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Yu CH, Davidson S, Harapas CR, Hilton JB, Mlodzianoski MJ, Laohamonthonkul P, Louis C, Low RRJ, Moecking J, De Nardo D, Balka KR, Calleja DJ, Moghaddas F, Ni E, McLean CA, Samson AL, Tyebji S, Tonkin CJ, Bye CR, Turner BJ, Pepin G, Gantier MP, Rogers KL, McArthur K, Crouch PJ, Masters SL. TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. Cell. 2020;183:636–649. e18. doi: 10.1016/j.cell.2020.09.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.